Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALECNASDAQ:ARVNNASDAQ:RLAYNASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.22+10.4%$1.15$0.87▼$6.78$121.99M0.76840,438 shs1.80 million shsARVNArvinas$6.49+3.7%$7.69$5.90▼$37.38$473.71M2.211.33 million shs1.94 million shsRLAYRelay Therapeutics$2.81+0.7%$2.87$1.78▼$10.72$481.76M1.652.08 million shs1.28 million shsZVRAZevra Therapeutics$8.66+2.7%$7.54$4.20▼$9.76$473.52M1.87637,468 shs1.47 million shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector0.00%+3.83%+32.59%-28.24%-78.41%ARVNArvinas0.00%-1.82%-24.53%-64.55%-79.93%RLAYRelay Therapeutics0.00%-6.64%+4.46%-29.75%-58.65%ZVRAZevra Therapeutics0.00%+10.04%+21.12%+7.31%+79.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALECAlector3.6602 of 5 stars3.12.00.04.51.91.70.6ARVNArvinas3.669 of 5 stars4.33.00.00.02.42.51.3RLAYRelay Therapeutics3.3618 of 5 stars4.41.00.00.04.02.50.6ZVRAZevra Therapeutics2.7603 of 5 stars4.60.00.00.03.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.14Hold$4.00227.87% UpsideARVNArvinas 2.60Moderate Buy$20.92222.29% UpsideRLAYRelay Therapeutics 2.83Moderate Buy$17.67528.71% UpsideZVRAZevra Therapeutics 3.11Buy$22.29157.34% UpsideCurrent Analyst Ratings BreakdownLatest ALEC, RLAY, ARVN, and ZVRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025ARVNArvinasUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $21.005/14/2025ZVRAZevra TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/14/2025ZVRAZevra TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.005/9/2025ALECAlectorHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.005/9/2025ARVNArvinasMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $11.005/7/2025RLAYRelay TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $10.005/5/2025ARVNArvinasCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.505/5/2025ARVNArvinasBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$20.00 ➝ $10.005/5/2025ARVNArvinasTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$21.00 ➝ $11.005/2/2025ARVNArvinasBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$16.005/2/2025ARVNArvinasWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$26.00 ➝ $19.00(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$88.34M1.38N/AN/A$1.41 per share0.87ARVNArvinas$426.90M1.11N/AN/A$8.17 per share0.79RLAYRelay Therapeutics$7.68M62.74N/AN/A$5.90 per share0.48ZVRAZevra Therapeutics$23.61M20.05N/AN/A$1.71 per share5.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$130.39M-$1.23N/AN/AN/A-257.54%-108.77%-27.03%N/AARVNArvinas-$198.90M-$0.66N/AN/AN/A-75.51%-33.75%-16.75%7/29/2025 (Estimated)RLAYRelay Therapeutics-$341.97M-$2.23N/AN/AN/AN/A-45.75%-40.75%8/5/2025 (Estimated)ZVRAZevra Therapeutics-$46.05M-$1.90N/A43.30N/A-342.63%-159.54%-51.50%N/ALatest ALEC, RLAY, ARVN, and ZVRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ZVRAZevra Therapeutics-$0.21-$0.06+$0.15-$0.06$16.96 million$20.40 million5/5/2025Q1 2025RLAYRelay Therapeutics-$0.50-$0.46+$0.04-$0.46$0.01 million$7.68 million5/1/2025Q1 2025ARVNArvinas-$0.93$1.14+$2.07$1.14$41.87 millionN/A3/11/2025Q4 2024ZVRAZevra Therapeutics-$0.39-$0.67-$0.28-$0.67$8.93 million$12.00 million2/26/2025Q4 2024ALECAlector-$0.61-$0.02+$0.59-$0.02$20.41 million$54.24 million2/26/2025Q4 2024RLAYRelay Therapeutics-$0.57-$0.45+$0.12-$0.45$5.53 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/AARVNArvinasN/AN/AN/AN/AN/ARLAYRelay TherapeuticsN/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlectorN/A3.293.29ARVNArvinasN/A4.644.64RLAYRelay TherapeuticsN/A18.4218.42ZVRAZevra Therapeutics0.842.882.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%ARVNArvinas95.19%RLAYRelay Therapeutics96.98%ZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipALECAlector9.10%ARVNArvinas4.73%RLAYRelay Therapeutics4.32%ZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector27099.99 million89.02 millionOptionableARVNArvinas42072.99 million65.18 millionOptionableRLAYRelay Therapeutics330171.45 million160.15 millionOptionableZVRAZevra Therapeutics2054.68 million52.10 millionOptionableALEC, RLAY, ARVN, and ZVRA HeadlinesRecent News About These CompaniesZevra Therapeutics' (ZVRA) "Overweight" Rating Reaffirmed at Cantor FitzgeraldMay 17 at 2:18 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Flora Growth (FLGC), Cardinal Health (CAH) and Zevra Therapeutics (ZVRA)May 16 at 11:45 AM | theglobeandmail.comWith 49% stake, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) seems to have captured institutional investors' interestMay 15 at 8:58 PM | finance.yahoo.comZevra Reports First Quarter 2025 Financial Results and Corporate UpdateMay 14, 2025 | taiwannews.com.twZevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comZevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue EstimatesMay 13, 2025 | zacks.comZevra Therapeutics, Inc. Q1 2025 Earnings PreviewMay 12, 2025 | msn.comZevra Therapeutics (ZVRA) Expected to Announce Earnings on WednesdayMay 9, 2025 | marketbeat.comZevra Therapeutics Announces Details for Q1 2025 Financial Results CallMay 6, 2025 | globenewswire.comBarclays PLC Increases Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)May 3, 2025 | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Buy" by BrokeragesMay 3, 2025 | marketbeat.com85,818 Shares in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Bought by Boothbay Fund Management LLCMay 2, 2025 | marketbeat.comZevra Therapeutics to Participate in the Citizens Life Science ConferenceMay 1, 2025 | finance.yahoo.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Sold by Nantahala Capital Management LLCApril 30, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Grows Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)April 28, 2025 | marketbeat.comGeode Capital Management LLC Has $9.91 Million Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)April 26, 2025 | marketbeat.comDiadema Partners LP Makes New Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)April 24, 2025 | marketbeat.comZevra Files Definitive Proxy Statement and Mails Letter to StockholdersApril 21, 2025 | finance.yahoo.comZevra Therapeutics urges stockholders to vote for director nomineesApril 21, 2025 | markets.businessinsider.comZevra Therapeutics Urges Stockholders to Vote "FOR" Qualified Directors Amid Proxy Contest ConcernsApril 21, 2025 | quiverquant.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Position Boosted by Altium Capital Management LLCApril 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALEC, RLAY, ARVN, and ZVRA Company DescriptionsAlector NASDAQ:ALEC$1.22 +0.12 (+10.41%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$1.21 -0.01 (-1.15%) As of 05/16/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Arvinas NASDAQ:ARVN$6.49 +0.23 (+3.67%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$6.35 -0.14 (-2.14%) As of 05/16/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Relay Therapeutics NASDAQ:RLAY$2.81 +0.02 (+0.72%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$2.82 +0.02 (+0.53%) As of 05/16/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Zevra Therapeutics NASDAQ:ZVRA$8.66 +0.23 (+2.73%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$8.53 -0.13 (-1.50%) As of 05/16/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/12 - 05/16 Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Plug Power: Is Q1 Noise An Opportunity for Accumulation? Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
